Bioanalytical Systems (NASDAQ:BASI) issued its earnings results on Wednesday. The company reported ($0.04) earnings per share for the quarter, Morningstar.com reports. The company had revenue of $10.86 million for the quarter. Bioanalytical Systems had a negative net margin of 2.82% and a negative return on equity of 3.12%.
NASDAQ BASI traded down $0.03 on Thursday, hitting $2.07. The company’s stock had a trading volume of 64,670 shares, compared to its average volume of 9,252. Bioanalytical Systems has a 52-week low of $1.18 and a 52-week high of $2.17. The company has a debt-to-equity ratio of 0.91, a quick ratio of 0.54 and a current ratio of 0.63. The firm’s 50-day simple moving average is $2.01.
Separately, ValuEngine cut Bioanalytical Systems from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th.
Bioanalytical Systems Company Profile
Bioanalytical Systems, Inc provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products.
Recommended Story: Why is insider trading harmful?
Receive News & Ratings for Bioanalytical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems and related companies with MarketBeat.com's FREE daily email newsletter.